Larimar Therapeutics, Inc. (LRMR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Larimar Therapeutics, Inc. (LRMR) closed at USD 2.09 on 2026-10-14, a change of -52 % over the past year, with a market capitalization of USD 206.73M.

Larimar Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Larimar Therapeutics, Inc. key figures

Previous close

USD 2.09 (2026-10-14)

1-year change

-52 %

Market cap

USD 206.73M

Enterprise value

USD 56.41M

P/E ratio (trailing)

-1.00

P/E ratio (forward)

-1.88

EPS (trailing)

-1.99

EPS (forward)

-1.06

PEG ratio

n/a

Price to book

1.63

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.22

Employees

71

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Larimar Therapeutics, Inc. and compare it with other stocks.